Macquarie University spinoff Fluorotechnics is establishing a reputation for lucrative liaisons with giants, announcing a global marketing agreement with Sigma Aldrich for its new-tech FluoroProfile protein-quantification kits.

Sydney biomaterials company Avastra (ASX:AVS) has halted its Bioweld human clinical trial due to unexpected results in its long-term animal study, although the company is still unsure what caused the unexpected results.

Keith Williams reflects on the long and winding road he has travelled as a player in the filed of protein science.

A new Biomarker Discovery Laboratory was opened today at Australian Proteomics Analysis Facility (APAF) at Macquarie University, approximately ten years after scientists including Keith Williams and Marc Wilkins initiated the science now known as 'proteomics' on that very site.

The Australian Proteome Analysis Facility (APAF) is gearing up to launch its new Biomarker Discovery Laboratory and is already on the verge of signing a pharmaceutical company partner for a project.

Researchers at Sydney's Garvan Institute have identified a gene coding for a cell-adhesion molecule in the brain as a strong risk factor for bipolar disorder, or manic depression.

The Australian Proteome Analysis Facility, headquartered at Sydney's Macquarie University, is to team up with global life science supplier Qiagen in a AUD$1m research project to develop more efficient ways of removing high-abundance proteins from serum samples.

Australian investors can now buy a piece of North Ryde-based biotechnology company Proteome Systems, the Australian company credited with pioneering the latter-day boom science of proteomics.

There must be something in the water in Sydney’s North Ryde that encourages biotech.

New Sydney biotechnology company Applimex Systems, Macquarie University’s latest spin-off, is commercialising microbes that, in the modern tabloid lexicon, qualify as 'superbugs'.

Market analysts are wondering whether the windown for Australian biotech IPOs has slammed shut.